APX001-202

APX001-202

To evaluate the safety and efficacy of APX001 for the treatment of adult patients aged 18 years and above with IMIs caused by Aspergillus spp. or rare molds, who have limited antifungal treatment options.


Study treatments

APX001 IV or oral for up to 42 days


Inclusion criteria

Exclusion criteria


Participating sites

Link